Clinical outcomes up to 5 years after implantation of the bioresorbable scaffold Absorb
| Clinical outcomes | 6 months | 1 year | 2 years | 5 years |
| Patients at follow-up (%) | 88/89 (99) | 87/89 (98) | 76/89 (85) | 71/89 (80) |
| Primary endpoint (%) | ||||
| DOCE | 6 (6.8) | 14 (16) | 22 (29) | 33 (46) |
| TVR | 6 (6.8) | 15 (17) | 23 (30) | 34 (48) |
| All TVR* | 6 | 16 | 26 | 49 |
| TV-MI | 2 (2.3) | 2 (2.3) | 3 (3.9) | 8 (11) |
| All TV-MI* | 2 | 2 | 3 | 10 |
| Cardiac death | 0 | 0 | 0 | 2 (2.8) |
| Secondary endpoints (%) | ||||
| Definite or probable ScT | 1 (1.1) | 1 (1.1) | 3 (3.9) | 6 (8.4) |
| TLR | 6 (6.8) | 15 (17) | 20 (26) | 31 (44) |
| All TLR* | 6 | 16 | 23 | 46 |
| All-cause death | 1 (1.1) | 2 (2.3) | 6 (7.9) | 14 (20) |
| CABG | 0 (0) | 0 (0) | 2 (2.6) | 5 (7) |
Data are presented as number (percentage).
*Cumulative events (one or more events per patient possible).
CABG, coronary artery bypass grafting; DOCE, device-oriented composite endpoint; ScT, scaffold thrombosis; TLR, target lesion revascularisation; TV-MI, target vessel myocardial infarction; TVR, target vessel revascularisation.